Alzheimer Updates, Stroke Breakthroughs, and the Case for Early Treatment
This article reviews current pharmacological and clinical approaches to managing Alzheimer's disease, focusing on agitation treatments and anti-amyloid therapies. It emphasizes the importance of clinical pharmacists in navigating complex treatment decisions and safety risks for elderly patients.
Why it matters
As new Alzheimer's treatments emerge, understanding their clinical limitations and the necessity of specialized oversight is critical for patient safety and effective care management.
1. New options for Alzheimer s agitation exist, but fit carefully into the treatment algorithm. Dextromethorphan/bupropion offers a novel NMDA-based mechanism for treating agitation in Alzheimer dementia, but its clinical effect size is modest, and it carries meaningful safety considerations—particularly around the bupropion component in elderly patients. Like all pharmacologic options in this space, it remains a later-line choice after nonpharmacologic interventions have been exhausted, and medication reconciliation is critical given its interaction potential with memantine and CYP2D6 inhibitors.
The content is a technical, evidence-based review focused on clinical practice and pharmaceutical guidelines without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in